Mutual of America Capital Management LLC Cuts Stock Position in Lantheus Holdings, Inc. $LNTH

Mutual of America Capital Management LLC trimmed its stake in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 27.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,154 shares of the medical equipment provider’s stock after selling 21,576 shares during the period. Mutual of America Capital Management LLC owned 0.08% of Lantheus worth $2,880,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of LNTH. Assenagon Asset Management S.A. purchased a new stake in Lantheus during the 3rd quarter worth approximately $65,654,000. Polaris Capital Management LLC acquired a new stake in shares of Lantheus in the third quarter worth approximately $32,687,000. Norges Bank purchased a new stake in shares of Lantheus during the second quarter worth approximately $32,631,000. Galvin Gaustad & Stein LLC acquired a new position in Lantheus in the 2nd quarter valued at $11,899,000. Finally, Boston Partners lifted its holdings in Lantheus by 30.5% in the 2nd quarter. Boston Partners now owns 576,362 shares of the medical equipment provider’s stock valued at $46,432,000 after purchasing an additional 134,781 shares in the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Stock Up 0.4%

Lantheus stock opened at $66.92 on Friday. The firm has a market capitalization of $4.44 billion, a P/E ratio of 28.12 and a beta of -0.11. The company has a current ratio of 2.67, a quick ratio of 2.49 and a debt-to-equity ratio of 0.51. Lantheus Holdings, Inc. has a twelve month low of $47.25 and a twelve month high of $111.29. The stock’s fifty day simple moving average is $64.87 and its 200-day simple moving average is $59.88.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share for the quarter, hitting the consensus estimate of $1.27. The company had revenue of $384.01 million for the quarter, compared to the consensus estimate of $363.42 million. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.Lantheus’s revenue was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.70 EPS. Lantheus has set its FY 2025 guidance at 5.500-5.650 EPS. As a group, equities analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on LNTH shares. Truist Financial upped their target price on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Mizuho lifted their target price on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 17th. Finally, The Goldman Sachs Group set a $77.00 price target on shares of Lantheus and gave the company a “neutral” rating in a research note on Wednesday, October 8th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $78.00.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.